Ann: Imugene Advances VAXINIA MAST Trial to Next IV Cohorts, page-167

Reon1, IMU are running to a plan. LC has been signalling that plan as IMU progresses.

What people tend to forget, is that these trials are open label. They can see everything real time. We get old information released to us. Management have made forward plans before we get updated.

As the post by Rich&Poor showed, IMU can submit a paper for peer review by the 28 June, This would include Cohort three MAST trial data. But can add late breaking news by 28 August. That gives IMU enough time to submit Cohort 4 data into the paper.

We have been told that Cohort 4 would likely be the Optimal Biological Dose. So it’s not just guesswork. We have been given all the information we need to see the business plan in action.

As we all know LC and YF don’t just randomly do and say things that don’t lead somewhere.